Research Article
NLRP3 Inflammasome Formation and Activation in Nonalcoholic Steatohepatitis: Therapeutic Target for Antimetabolic Syndrome Remedy FTZ
Figure 8
Involvement of HMGB1 in lipid deposition in HSCs treated with PA with and without FTZ treatment. (a) Representative oil red O images showing positive staining of lipid deposition in PA-treated HSCs, which was enhanced by HMGB1 but suppressed by FTZ and GLY, an inhibitor of HMGB1. (b) Staining area of lipid deposition showing a statistically significant increase induced by PA, which was enhanced by HMGB1, but reduced by FTZ and HMGB1 inhibitor, GLY ( batches of cells). versus PA-Vehl group; versus PA-HMGB1-Vehl group.
(a) |
(b) |